Sign In
Buy CGEN
$2.19
-0.0700 (-3.10%)
At Close: Jun 03, 2026
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
07:00am, Monday, 28'th Jul 2025
HOLON, Israel , July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025
07:00am, Wednesday, 23'rd Jul 2025
HOLON, Israel , July 23, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
07:00am, Monday, 21'st Jul 2025
Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong biological rationale and
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
07:00am, Thursday, 12'th Jun 2025
HOLON, Israel , June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
12:56pm, Monday, 19'th May 2025
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.
Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
10:21am, Monday, 19'th May 2025
Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CE
Compugen Reports First Quarter 2025 Results
07:00am, Monday, 19'th May 2025
Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM5
Compugen Announces Leadership Transitions Effective September 2025
07:00am, Tuesday, 13'th May 2025
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of Directors Eran Ophir, Ph.D.
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025
07:00am, Monday, 05'th May 2025
HOLON, Israel , May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
07:00am, Wednesday, 26'th Mar 2025
HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announce
Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript
10:34am, Tuesday, 04'th Mar 2025
Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
09:15am, Tuesday, 04'th Mar 2025
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago.
Compugen Reports Fourth Quarter and Full Year 2024 Results
07:00am, Tuesday, 04'th Mar 2025
Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenan
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
07:00am, Monday, 03'rd Mar 2025
HOLON, ISRAEL , March 3, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announc
Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand tumor biol
